Myriad Genetics Will Present Results from Six Breast Cancer Studies at SABCS
November 28 2016 - 7:05AM
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular
diagnostics and personalized medicine, announced today that the
Company will present six breast cancer studies at the 2016 San
Antonio Breast Cancer Symposium (SABCS) being held Dec. 6-10, 2016
in San Antonio, Texas.
“Myriad Genetics is proud to offer the highest-quality molecular
diagnostic tests designed to help prevent breast cancer and improve
health outcomes for those with breast cancer,” said Johnathan
Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetic
Laboratories. “We’re excited to present six new studies at SABCS
this year, including data on: EndoPredict®, a second-generation
test that predicts the risk of recurrence; myRisk™ Hereditary
Cancer, the gold standard test to identify people at risk for
hereditary breast cancer; and myChoice® HRD, an innovative, novel
companion diagnostic test to identify optimal pharmaceutical
decisions for patients.”
A list of the Myriad presentations at SABCS is below.
Follow Myriad on Twitter via @MyriadGenetics and stay
informed about symposium news and updates by using the hashtag
#SABCS16.
EndoPredict Presentation
- Title: Comprehensive comparison of prognostic
signatures for breast cancer in
TransATAC.Presenter: Ivana
Sestak.Date: Friday, Dec.9, 2016: 4:15 p.m.
CT.Location: S6-05; General Session 6 - Hall
3.
myRisk Hereditary Cancer Presentations
- Title: Genetic testing for Hereditary Breast
and Ovarian Cancer Syndrome among women with a personal diagnosis
of breast cancer in patients with Medicaid as compared to patients
with private insurance.Presenter: Paul
Baron.Date: Thursday, Dec. 8, 2016: 5:00 - 7:00
p.m. CT.Location: Poster P3-10-06.
- Title: Trends in age of breast cancer
diagnosis for women with pathogenic variants in genes associated
with increased breast cancer risk.Presenter: Heidi
Gorringe.Date: Thursday, Dec. 8, 2016: 5:00 - 7:00
p.m. CT.Location: Poster P3-08-04.
myChoice HRD Presentations
- Title: Homologous repair deficiency (HRD) as a
measure to predict the effect of carboplatin on survival in the
neoadjuvant phase II trial GeparSixto in triple-negative early
breast cancer.Presenter: Gunter von
Minckwitz.Date: Wednesday, Dec. 7, 2016: 5:00 -
7:00 p.m. CT.Location: Poster P1-09-02.
- Title: BRCA1 methylation status, silencing and
treatment effect in the TNT trial: A randomized phase III trial of
carboplatin compared with docetaxel for patients with metastatic or
recurrent locally advanced triple negative or BRCA1/2 breast cancer
(CRUK/07/012).Presenter: Andrew
Tutt.Date: Friday, Dec. 9, 2016: 3:15 p.m.
CT.Location: S6-01; General Session 6 - Hall
3.
- Title: Evaluation of tumor infiltrating
lymphocytes (TILs) and their association with homologous
recombination deficiency and BRCA1/2 mutation status in
triple-negative breast cancer (TNBC): A pooled
analysis.Presenter: Melinda
Telli.Date: Saturday, Dec. 10, 2016: 7:30 - 9:00
a.m. CT.Location: Poster P6-09-09.
For more information about these presentations, please visit the
SABCS website at https://www.sabcs.org/.
About Myriad GeneticsMyriad Genetics Inc., is a
leading personalized medicine company dedicated to being a trusted
advisor transforming patient lives worldwide with pioneering
molecular diagnostics. Myriad discovers and commercializes
molecular diagnostic tests that: determine the risk of developing
disease, accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on three
strategic imperatives: transitioning and expanding its hereditary
cancer testing markets, diversifying its product portfolio through
the introduction of new products and increasing the revenue
contribution from international markets. For more information on
how Myriad is making a difference, please visit the Company's
website: https://www.myriad.com/.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan,
BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra,
Prolaris and GeneSight are trademarks or registered trademarks of
Myriad Genetics, Inc. or its wholly owned subsidiaries in the
United States and foreign countries. MYGN-F,
MYGN-G
Safe Harbor StatementThis press release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
related to EndoPredict, myRisk Hereditary Cancer and my Choice HRD
data being presented at the 2016 San Antonio Breast Cancer
Symposium being held Dec. 6-10, 2016 in San Antonio, Texas; and the
Company's strategic directives under the caption "About Myriad
Genetics." These “forward-looking statements” are based on
management’s current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those described or
implied in the forward-looking statements. These risks include, but
are not limited to: the risk that sales and profit margins of our
existing molecular diagnostic tests and pharmaceutical and clinical
services may decline or will not continue to increase at historical
rates; risks related to our ability to transition from our existing
product portfolio to our new tests; risks related to changes in the
governmental or private insurers’ reimbursement levels for our
tests or our ability to obtain reimbursement for our new tests at
comparable levels to our existing tests; risks related to increased
competition and the development of new competing tests and
services; the risk that we may be unable to develop or achieve
commercial success for additional molecular diagnostic tests and
pharmaceutical and clinical services in a timely manner, or at all;
the risk that we may not successfully develop new markets for our
molecular diagnostic tests and pharmaceutical and clinical
services, including our ability to successfully generate revenue
outside the United States; the risk that licenses to the technology
underlying our molecular diagnostic tests and pharmaceutical and
clinical services tests and any future tests are terminated or
cannot be maintained on satisfactory terms; risks related to delays
or other problems with operating our laboratory testing facilities;
risks related to public concern over our genetic testing in general
or our tests in particular; risks related to regulatory
requirements or enforcement in the United States and foreign
countries and changes in the structure of the healthcare system or
healthcare payment systems; risks related to our ability to obtain
new corporate collaborations or licenses and acquire new
technologies or businesses on satisfactory terms, if at all; risks
related to our ability to successfully integrate and derive
benefits from any technologies or businesses that we license or
acquire, including but not limited to our acquisition of Assurex,
Sividon and the Clinic; risks related to our projections about the
potential market opportunity for our products; the risk that we or
our licensors may be unable to protect or that third parties will
infringe the proprietary technologies underlying our tests; the
risk of patent-infringement claims or challenges to the validity of
our patents; risks related to changes in intellectual property laws
covering our molecular diagnostic tests and pharmaceutical and
clinical services and patents or enforcement in the United States
and foreign countries, such as the Supreme Court decision in the
lawsuit brought against us by the Association for Molecular
Pathology et al; risks of new, changing and competitive
technologies and regulations in the United States and
internationally; the risk that we may be unable to comply with
financial operating covenants under our credit or lending
agreements; the risk that we will be unable to pay, when due,
amounts due under our credit or lending agreements; and other
factors discussed under the heading “Risk Factors” contained in
Item 1A of our Annual report on Form 10-K for the fiscal year ended
June 30, 2016, which has been filed with the Securities and
Exchange Commission, as well as any updates to those risk factors
filed from time to time in our Quarterly Reports on Form 10-Q or
Current Reports on Form 8-K.
Media Contact:
Ron Rogers
(908) 285-0248
rrogers@myriad.com
Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Sep 2023 to Sep 2024